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Abstract
Background: Rigorous, informative meta-analyses rely on availability of appropriate summary statistics or individual
participant data. For continuous outcomes, especially those with naturally skewed distributions, summary
information on the mean or variability often goes unreported. While full reporting of original trial data is the ideal,
we sought to identify methods for handling unreported mean or variability summary statistics in meta-analysis.
Methods: We undertook two systematic literature reviews to identify methodological approaches used to deal with
missing mean or variability summary statistics. Five electronic databases were searched, in addition to the Cochrane
Colloquium abstract books and the Cochrane Statistics Methods Group mailing list archive. We also conducted cited
reference searching and emailed topic experts to identify recent methodological developments. Details recorded
included the description of the method, the information required to implement the method, any underlying
assumptions and whether the method could be readily applied in standard statistical software. We provided a
summary description of the methods identified, illustrating selected methods in example meta-analysis scenarios.
Results: For missing standard deviations (SDs), following screening of 503 articles, fifteen methods were identified in
addition to those reported in a previous review. These included Bayesian hierarchical modelling at the meta-analysis
level; summary statistic level imputation based on observed SD values from other trials in the meta-analysis; a practical
approximation based on the range; and algebraic estimation of the SD based on other summary statistics. Following
screening of 1124 articles for methods estimating the mean, one approximate Bayesian computation approach and
three papers based on alternative summary statistics were identified. Illustrative meta-analyses showed that when
replacing a missing SD the approximation using the range minimised loss of precision and generally performed better
than omitting trials. When estimating missing means, a formula using the median, lower quartile and upper quartile
performed best in preserving the precision of the meta-analysis findings, although in some scenarios, omitting trials
gave superior results.
Conclusions: Methods based on summary statistics (minimum, maximum, lower quartile, upper quartile, median)
reported in the literature facilitate more comprehensive inclusion of randomised controlled trials with missing mean or
variability summary statistics within meta-analyses.
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Background
Systematic review and meta-analysis of clinical trial results
is considered the highest level of evidence [1] and provides
a readily accessible synthesis of the evidence on the effect-
iveness of a given treatment. Given the influential role of
meta-analysis in shaping clinical guidelines and in turn pa-
tient care, it is critical that reviews summarise the available
research findings with minimum bias and maximum pre-
cision, in order to provide conclusions that are of use to
patients and healthcare professionals and that act as an
effective guide to future research priorities.
Although reviewers use systematic and transparent
methods to minimise bias and random variability in their
evaluations of interventions [2], selective or incomplete
reporting of trials is problematic [3] and can lead to im-
precision and biases in meta-analysis findings.
In the absence of individual participant data, the
standard approach to meta-analysis of continuous out-
comes requires information on the mean and either the
standard deviation (SD), variance or standard error (SE)
values for each treatment group [4]. Where continuous
outcomes have a skewed distribution, incomplete report-
ing of the SD and mean is more widespread: often other
summaries are reported, with the quartiles or minimum
and maximum being given instead of the SD and the
median being stated in place of the mean.
In such situations, the systematic reviewer must either
exclude the trial from the meta-analysis – with accom-
panying concerns over the introduction of potential for
bias and the loss of precision – or find an alternative
method of deriving the missing mean or SD information
based on information available in the trial report.
A previous systematic review [5] identified a range of
possible methods for replacing missing SD values and
concluded that this diversity of approaches implied in-
consistency within the systematic review community and
suboptimal choice of methods by many. Hozo and col-
leagues [6] present formulae for estimating the mean
value on the basis of other summary statistics and con-
clude that imputation of the median value is not always
adequate, particularly where the sample size is small.
In this paper we update the systematic review of meth-
odology for handling missing SD values and provide a
corresponding review of approaches to determining the
mean value where this is missing from a clinical trial re-
port. We also consider whether the methods identified
could be readily applied by systematic review teams,
without recourse to specialist software.
Methods
Aims
The first aim of this review was to provide an update on
new developments since a previous review [5] of
methods, in the meta-analysis context, of determining
the variance, SD or SE where these are missing from the
original trial report. Methods applicable to parallel group
or crossover randomised controlled trials were consid-
ered. Our second aim was to provide a systematic review
of the methods available to determine the mean value,
where this is missing from the original trial report.
Finally, we generated illustrative meta-analysis scenarios
based on individual participant data from a large com-
pleted stroke trial [7] to demonstrate the use of the most
readily applicable methods and to compare their
performance.
Overall review strategy
Full details of the data sources for each review topic are
given below. Following removal of duplicates and articles
published outside the time limits of the review, a single
reviewer (IB) screened articles for relevance on the basis
of the title and abstract, and then performed a full text
review of promising articles to allow formal assessment
of eligibility. The full text of articles considered poten-
tially eligible was assessed by an independent reviewer
(CJW) to confirm inclusion; any disagreements were re-
solved via discussion. Pre-specified information from
identified papers was recorded jointly by the two
reviewers.
Details sought from included articles were the descrip-
tion of the method being proposed, the information re-
quired to implement the method and any underlying
assumptions. We also considered whether an update to
the Cochrane RevMan software [8] would be needed to
apply the method and whether it could be readily imple-
mented in other standard statistical software. The find-
ings for the two review topics were summarised
descriptively and critically appraised. The search strategy
included grey literature to minimise the risk of
publication bias.
Search strategy for missing variance/SD/SE methods
To identify new methods applicable when the variance, SD
or SE is missing from the original clinical trial report, we
searched the electronic databases MEDLINE, EMBASE,
Web of Knowledge, PsycINFO and Global Health. A com-
plex search strategy, developed in consultation with a li-
brarian with bibliographic database searching expertise, was
required to provide a specific yet sensitive search; these
terms were then tailored to each electronic search engine.
We searched for terms such as “derived”, “missing” and
“imputed” combined with “variance”, “SD” and “SE”. As an
example, the EMBASE search strategy is given in Add-
itional file 1 fig. S1 and illustrates the detail of terms re-
quired to obtain a sufficiently specific search which still
captures a known key reference [5]. We also searched the
grey literature, including Cochrane Colloquium abstract
books and the Cochrane Statistics Methods Group mailing
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list archive. We extended this search to identify recent
methodology developments by emailing topic experts on
the Cochrane Statistics Methods Group. Full text of arti-
cles was obtained from Journals@Ovid (OVFT),
YourJournals@Ovid, PsycARTICLES Full Text,
Books@Ovid or via inter-library loan.
We included methods belonging to five of the categor-
ies identified by Wiebe et al. [5]: 1. Methods to derive
the variance/SD/SE algebraically, for example from para-
metric test statistics or p-values; 2. Summary statistic
level imputation of the variance/SD/SE (described as
“study-level” imputation in Wiebe et al. [5]), for example
substituting SD data from other studies, using the coeffi-
cient of variation, non-parametric summaries, or correl-
ation data; 3. Meta-analysis level strategies, for example
multiple imputation or bootstrapping; 4. Methods to
meta-analyse effects on continuous outcomes without
using individual study variance/SD/SE; 5. Methods to
impute effect size, from which the variance/SD/SE could
be derived. Publications from 2002 onwards were in-
cluded, to ensure complete coverage of the period fol-
lowing that covered by the review of Wiebe et al. [5].
A study was excluded if it presented methods that
could not be applied to continuous outcomes or that ap-
plied to statistics other than the variance, SD or SE.
Papers which applied a technique but did not present
new methodology were also excluded.
Search strategy for missing mean methods
To identify novel methods applicable when the mean is
missing from the original clinical trial report, we initially
planned to search the same electronic databases, full text
and grey literature sources as in the missing variance/
SD/SE review. Based on the considerable overlap in that
review between hits identified from different electronic
sources, we performed a more restricted search using
EMBASE and grey literature only, plus a targeted Web
of Knowledge search to identify references which cited
Hozo et al. [6]. The EMBASE search strategy is given in
online Additional file 2 fig. S2. Again, we augmented this
search for recent methodology developments by survey-
ing the Cochrane Statistics Methods Group members.
The inclusion and exclusion criteria remained in place
from the first review. Publications from 2005 onwards
were included: Hozo and colleagues [6] had already
summarised previously available methods.
Method evaluation using individual participant data
Using individual participant data [7] we generated meta-
analyses to illustrate the most readily applicable statis-
tical methods for replacing missing variability or mean
values. We selected methods which could be imple-
mented without specialist software or statistical pro-
gramming. We compared the performance of each
method to analysis of the complete data (with no
missing summary statistics) using
1. its bias (difference between the estimated and true
values of the intervention effect), and
2. its imprecision (ratio of the widths of the confidence
intervals for the intervention effect [width when
estimating missing SD or mean: width when all
summary statistics available])
We also compared the performance of each statistical
method to the strategy of omitting any trials with miss-
ing SD or mean values from the meta-analysis.
We analysed hospital length of stay, an outcome with a
skewed distribution for which the SD and mean summary
statistics might well be omitted from published trial re-
ports. The intervention effect was the mean difference in
days, estimated using random effects meta-analysis fitted
in the Cochrane RevMan software v5.3 [8].
The exemplar data set from the carotid surgery rando-
mised trial [7] contains data on 3526 participants from 95
sites in 24 countries. For these illustrative analyses, we se-
lected sites that included 15 or more participants (58 sites;
3268 participants). Meta-analyses scenarios were gener-
ated in which each site represented a separate trial,
covering various sample sizes and numbers of ‘trials’.
The methods for estimating missing SD or mean
values were explored across several meta-analysis
scenarios in a fractional factorial design. The factors
considered were: (1) number of trials in the meta-
analysis (5, 10, 20, 30); (2) trial size: small, large or
mixed, containing a mean of 23, 87 and 60 participants
per trial respectively; (3) number of trials with missing
data (2 for meta-analyses containing 5 trials; 2 and 5 for
10-trial meta-analyses; 5 and 10 for 20-trial meta-
analyses; 5, 10 and 15 for 30-trial meta-analyses); and (4)
size of the trials with missing summary statistics (small,
large or randomly selected).
Results
In the description of methods, we use the notation: a,
minimum value; q1, lower quartile; m, median; q3, upper
quartile; b, maximum; n, sample size; and x , sample
mean.
Missing variance/SD/SE methods
The variance/SD/SE search was run on 12 November
2014 and updated using cited reference searching on 4
April 2016 and the survey of Cochrane topic experts in
May 2016. Fig. 1 illustrates the numbers of papers iden-
tified, screened, assessed for eligibility and included.
Two hundred and thirty-eight were assessed for eligibil-
ity following title and abstract screening. Of these, 161
of potential interest were identified; most were previous
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methodology reviews (2) or systematic review papers
(144) which did not present new methodology.
Table 1 summarises details of the articles included. Nine
of the 15 methods identified (Abrams et al. [9], Sung et al.
[10], Nixon et al. [11], Dakin et al. [12], MacNeil and
Graham [13], Stevens [14], Stevens et al. [15], Boucher
[16] and Kwon and Reis [17]) are set in a Bayesian
framework.
Category 1. Methods to derive SD/SE/variance
algebraically
Walter and Yao [18] present a readily applicable im-
provement to a method based on the minimum and
maximum observed values of the outcome. This “range”
method, whereby the difference between minimum and
maximum values is divided by 4 to estimate the SD, was
originally presented by Mendehall and colleagues [19] in
the survey sampling context. In this update, a lookup
table of conversion factors from range to SD, based on
the distributional results of Tippett [20] for the range, is
presented for a variety of sample sizes. They illustrate
the method in two example studies of interventions to
improve adherence to randomised treatment in rheuma-
toid arthritis and human immunodeficiency virus. They
caution that non-Normality of outcomes, whether
through skewness or kurtosis, may invalidate their
tabulated conversion factors but note that the very pres-
ence of skewness might be the cause of the minimum
and maximum being reported instead of the SD. They
observe that although in theory the use of certain inter-
ior order statistics may perform better on skewed out-
comes than their proposed method, in practice such
statistics would never be available in trial reports; they
conclude that their method offers an acceptable com-
promise in the absence of the original data being obtain-
able from the original trial publication authors.
Hozo and colleagues [6] present a formula (see Table
1) for estimating the variance where values for the mini-
mum, median, maximum and sample size are available.
In simulations of outcomes from a range of parametric
distributions, they find that their approximation per-
forms best on Normally distributed data when the sam-
ple size is very small but methods based on dividing the
range by 4 and 6 are superior for sample sizes from 16
to 70 and over 70 respectively. Similar patterns are ob-
served on skewed outcomes simulated from log-Normal,
beta, exponential and Weibull distributions. In simulated
meta-analyses, they conclude that their variance estima-
tion formula may miss the true value by a margin be-
tween 10% and 20%.
Bland [21] presents a formula for the variance
(Table 1) which makes use of the lower quartile and
upper quartile in addition to the minimum, median
Fig. 1 Systematic review of methods to derive missing variance/SD: PRISMA Flow Diagram.Flow diagram based on: Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med
6(6): e1000097. doi:https://doi.org/10.1371/journal.pmed1000097
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Table 1 Summary of methods identified for replacing missing variance/SD/SE
Method Category Description Statistics
required
Assumptions Software implementation
Abrams
et al.
(2005)
3 Bayesian meta-analysis estimates
within-patient correlation between
baseline and follow-up; enables
imputation of mean change from
baseline and its SD when only
baseline and follow-up means
and SDs reported
• baseline
mean/SD
• follow-up mean/SD
• change from baseline
mean/SD in some
included studies
SD at baseline same as SD at
follow-up; within subject
correlation comes from same
distribution for all studies and
treatment arms; careful choice
of prior distribution for
variance parameters
Example WinBUGS [24] code
provided in paper
Hozo
et al.
(2005)
1 Missing variance estimated for
example as:
• minimum
• median
• maximum
• sample size
Data normally distributed Excel spreadsheet provided
by Wan et al. (2014)
Var ≈ ðnþ1Þ
48nðn−1Þ2 þ ððn2 þ 3Þða−2mþ bÞ
2 þ 4n2ðb−aÞ2Þ
Sung
et al.
(2006)
3 Imputation of missing variances
within Bayesian meta-analysis
assuming distributed as
True variance * χ2 (n-1)/(n-1) where
true variance distributed as
log-normal
• variances reported
for other included
studies
Assume missing variances
come from same lognormal
distribution as reported
variances
Implemented in WinBUGS;
code supplied in online
supplement to article
Walter
and Yao
(2007)
1 Improved version of “range” method
which calculates SD = (b-a)/4
• sample size
• range or
min/max
Approximate normality Lookup table in paper could
readily be implemented in
standard software; RevMan
[8] could accommodate in
update
Ma
et al.
(2008)
2 Impute weighted average of
variances observed in other studies;
or calculate a range of pooled
estimates for efficacy based on the
smallest and largest variances
observed
• sample size
• variances of other
studies in
meta-analysis
Unobserved and observed
variances come from the same
underlying distribution
Could readily be
implemented in any
statistical software
Nixon
et al.
(2009)
3 Impute missing change from
baseline SD values in Bayesian
random effects meta-regression
• baseline SD
• follow-up SD
Log transform of baseline SD,
follow-up SD and change from
baseline SD follow trivariate
normal distribution. Where
follow-up SD is based on
complete cases, imputation
assumes non-informative
drop-out
Applied in WinBUGS
Dakin
et al.
(2010)
3 Bayesian hierarchical modelling
estimating SD values in context of
network meta-analysis. SD assumed
to follow gamma distribution;
parameters estimated from studies
reporting SDs
• observed SDs Observed and missing SD
values come from the same
gamma distribution
WinBUGS code provided in
publication
MacNeil
et al.
(2010)
3 Impute missing SDs in hierarchical
Bayesian meta-analysis based on
posterior predictive distribution
• observed SDs Observed, missing SDs arise
from same gamma distribution
Implemented in PyMC
Markov chain Monte Carlo
(MCMC) toolkit [31] of
Python [32]; code given in
online supplement
Stevens
(2011),
Stevens
et al.
(2012)
3 Bayesian network meta-analysis that
enables imputation of missing SDs
via posterior predictive distribution
(variances assumed to follow
gamma distribution)
• observed variances Variances follow gamma
distribution; log(SD) given
weak uniform prior distribution
WinBUGS code provided
Boucher
(2012)
3 Emax model of SDs; implemented
using either maximum likelihood or
hierarchical Bayesian model
• observed SDs over
time in longitudinal
study
longitudinal modelling of SDs
using Emax mixed effects
model; differences by
treatment group permitted in
SDs; weak uniform prior for SD
used in Bayesian approach
SAS (SAS Institute Inc., Cary,
NC) PROC NLMIXED and
WinBUGS code provided for
maximum likelihood and
Bayesian approaches
respectively
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and maximum. In simulations, Bland demonstrates
that his formula overestimates the standard deviation
at larger sample sizes where the underlying distribu-
tion is Normal; the issue is exacerbated for skewed
outcomes. Nevertheless, in both situations the for-
mula provides a less biased estimate than that of
Hozo et al. [6]. The over-estimation is attributed to
the greater chance of extreme outliers occurring in
large sample sizes, thus inflating the estimation of the
variance through the minimum and maximum values.
He considers that the method will still be useful,
since studies in meta-analyses with a small sample
size are most likely to be the ones with unreported
SD values and source data that cannot be obtained
from the trial report authors.
Continuing the theme of estimation based on sum-
mary statistics, Wan et al. [22], due to concerns over the
restrictive non-negative data assumption and the arbitrary
sample size thresholds guiding choice of formula in the
method of Hozo and colleagues [6], propose an improve-
ment using the same summary statistics:
SD ≈
b−a
2Φ−1
n−0:375
nþ 0:25
 
and an enhancement to the approach of Bland [21]
that additionally takes account of sample size with
the aim of reducing overestimation at larger sample
sizes:
SD ≈
b−a
4Φ−1
n−0:375
nþ 0:25
 þ q3−q1
4Φ−1
0:75n−0:125
nþ 0:25
 
Finally, using only the lower quartile, upper quartile
and sample size, they propose the following estimate:
SD ≈
q3−q1
2Φ−1
0:75n−0:125
nþ 0:25
 
and note its similarity to the Cochrane Handbook [4]
estimator
SD ≈
q3−q1
1:35
Through simulations, they demonstrate superior es-
timation properties, for both Normal and skewed
data, of their respective extensions to the methods of
Hozo and Bland. They also illustrate that a valid esti-
mate of the SD may also be made when the mini-
mum and maximum are unavailable but the upper
and lower quartiles are reported.
Kwon and Reis [17] apply simulation-based approxi-
mate Bayesian computation (ABC) in estimating missing
SD values based on other summary statistics available in
the trial report. The likelihood function for Bayesian
inference is unlikely to be evaluable, due to the
Table 1 Summary of methods identified for replacing missing variance/SD/SE (Continued)
Method Category Description Statistics
required
Assumptions Software implementation
Wan et al.
(2014)*
1 SD ≈ q3−q1
2Φ−1ð0:75n−0:125nþ0:25 Þ
• lower quartile
• upper quartile
• sample size
Data normally distributed Excel spreadsheet provided
by Wan et al. (2014)
Bland
(2015)
1 Missing variance estimated as: • minimum
• lower quartile
• median
• upper quartile
• maximum
• sample mean
Data normally distributed Excel spreadsheet provided
by Wan et al. (2014)
Var ≈ 1n−1 ð½2ðnþ3Þðq12þm2þq32Þþ2ðn−5Þða:q1þm:q1þm:q3þq3:bÞþðnþ11Þða2þb2Þ16 −nx2Þ
Kwon and
Reis (2015)
1 Approximate Bayesian computation
to estimate SD
• available summary
statistics
Underlying distribution of data R code provided
Chowdhry
et al.
(2016)
2 Meta-regression assuming sample
variances follow gamma distribution
• observed variances
from other studies in
meta-analysis
• study covariates
Variances missing at random
(MAR) and follow a gamma
distribution
Can be fitted in SAS PROC
NLMIXED
a minimum value, q1 lower quartile, m median, q3 upper quartile, b maximum, n sample size, x, sample mean
*Also provide formulae for scenarios where only a, b and n are available; or where a, b, q1, q3, and n are available; see Results section for details
Key to category numbers:
1 Methods to derive the variance/SD/SE algebraically from parametric test statistics, p-values, etc
2 Summary statistic level imputation of variance/SD/SE, for example substituting SD data from other studies, using coefficient of variation, non-parametric
summaries, or correlation data
3 Meta-analysis level strategies, for example multiple imputation or bootstrapping
4 Methods to meta-analyse effects on continuous outcomes without using individual study variance/SD/SE
5 Methods to impute effect size, from which variance/SD/SE could be derived
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unavailability of all data points from the source trials in
a meta-analysis. They therefore propose ABC, which re-
places the likelihood by using a distance measure – in
this example the Euclidean distance – to compare sum-
mary statistics between the observed and simulated data.
The prior distribution for the outcome must be speci-
fied: they propose that the underlying probability distri-
bution (for example, Normal or log-Normal) may be
determined based on background knowledge of the
outcome, and a uniform prior should be placed on
each parameter of this distribution, informed by the
available summary statistics. Many sets of candidate
parameter values are then generated from this prior,
and from these, many pseudo-data sets. Each of the
pseudo data sets is then compared to the observed
summary statistics and accepted if these are suffi-
ciently close (for example in the top 0.1% smallest
Euclidean distances). This accepted set of parameter
values is then used to estimate the parameter of
interest, in this case the SD. In simulations of out-
comes from Normal and skewed distributions, they
find the ABC method performs consistently better for
skewed distributions than the formulae of Hozo,
Bland and Wan. ABC does not perform as well when
the sample size is less than about 40 and the method
of Wan et al. [22] is superior for Normally distributed
outcomes.
Category 2. Summary statistic level imputation
Ma et al. [23] present two summary statistic level im-
putation methods which make use of the variances
observed in other trials in the meta-analysis. In the
first (termed the “prognostic” method) they calculate
the average of the observed variances and use this in
the study with missing variance information. In the
second (the “interval method”) they calculate a range
of pooled estimates for efficacy by imputing, for trials
with missing variances, the minimum and maximum
of the variances observed in other trials in the meta-
analysis. They illustrate the methods in meta-analyses
of drugs for patients with type 2 diabetes and inter-
ventions to lower intra-ocular pressure in open angle
glaucoma or intraocular hypertension. They conclude
that the prognostic method is preferable and also
gives more stable results than the policy of omitting
trials with missing variance summary statistics from a
meta-analysis. They caution that if the trials with ob-
served variances are small, the resulting imprecision
in these estimates will lead to poor performance of
the prognostic method.
Category 3. Meta-analysis level strategies
Abrams et al. [9] accommodate differences in meth-
odology among included trials (for example, where
outcome is reported at a given follow-up point rather
than as a change from baseline). This can lead to
missing information on, for example, the SD of mean
change from baseline. Their proposed solution (in
contrast to single imputation methods or omission of
studies not reporting change from baseline summary
statistics) is to adopt a fully Bayesian approach in
which external information is used to build a prior
distribution for the within-patient correlation between
baseline and follow-up measures, thus enabling appro-
priate estimation of the SD of the change from base-
line where only the baseline, and follow-up SD values
have been reported. A Uniform(0,1) vague prior for
the correlation ρ is used. Where external evidence is
available, this prior is replaced by performing a Bayes-
ian meta-analysis of the Fisher transformations Sj of
the observed ρj from external studies j = 1,…,J; a
vague Normal prior with mean δ is placed on the Sj
and the back-transformation ρ ¼ e2δ−1e2δþ1 is used. They
conclude that such an approach gives a substantial
improvement to meta-analysis estimation of the
pooled mean difference compared to applying a fixed
value for ρ. They note the conclusions are sensitive
to the choice of prior distribution, particularly when a
limited number of studies is included in the meta-
analysis, and that study-level covariates may be in-
cluded to incorporate greater flexibility in the prior
for ρ.
Sung et al. [10] incorporate continuous outcomes
with missing variances in a Bayesian meta-analysis by
estimating the distribution of reported variances and
applying multiple imputation of missing variances, as-
suming that these arose from this “parent” log-
Normal distribution. Specifically, the missing variance
is assumed to be distributed as the true variance,
multiplied by a χ2 distribution divided by its degrees
of freedom. The degrees of freedom equal n-1, where
n is the sample size of the trial with unreported vari-
ance. This is a special case of a gamma distribution,
with shape (n-1)/2 and scale (n-1)/(2 * true variance).
Sung et al. contend that their approach offers advan-
tages, in comparison to discarding information from
studies with unreported variances, and consider it
more straightforward to implement in a Bayesian
framework using the WinBUGS software than it
would be to employ a frequentist equivalent.
In a systematic review of valsartan in the treatment of
hypertension, Nixon et al. [11] impute missing SD values
within a Bayesian random effects meta-regression. The
missing data imputation model assumes a trivariate nor-
mal distribution for the log-transformed baseline SD,
follow-up SD and change from baseline SD. The follow-
ing relationship between the SD measures is exploited:
S2di ¼ S21i þ S22i−2ρ12S1iS2i , where Sdi , S1i and S2i are the
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change from baseline SD, baseline SD and follow-up SD
respectively, and ρ12 is the within-patient correlation be-
tween baseline and follow-up. The variance of observed
SDs is weighted by the inverse of the sample size. The
meta-regression allows adjustment for study-level char-
acteristics, such as mean baseline value, which may in-
fluence the treatment effect. As with other imputation
approaches identified in this review, the missing at
random assumption applies.
Dakin et al. [12], in the context of a mixed treatment
comparison meta-analysis, perform Bayesian modelling
of SDs contained in trial reports. They estimate the
gamma distribution that these follow and sample values
from that distribution to impute the SD for studies in
which this is missing, while still enabling the uncertainty
around these imputed values to be taken into account in
the meta-analysis. The unreported SD values are as-
sumed to be missing completely at random.
Within the setting of a hierarchical Bayesian meta-
analysis of the biogeographical relationship between
coral reef loss and populations of fish that rely on coral,
MacNeil and Graham [13] impute missing standard de-
viations from their posterior predictive distribution
based on the observed SD data. Again, any missing SDs
are assumed missing completely at random and the un-
certainty in imputed values is retained in the subsequent
hierarchical meta-analysis.
In the framework of a network meta-analysis, Stevens
[14] generates the posterior predictive distribution of
missing variances via Markov Chain Monte Carlo using
WinBUGS [24], assuming a gamma distribution for the
observed variances. The log-transformed SD values are
given a weak uniform prior. Using an example data set
where the true study and treatment group specific SDs are
known, he illustrates that the assumption of a common
standard deviation (missing completely at random) may
not be tenable and that violation of this leads to problems
in pooled treatment effect estimation. He further high-
lights the importance of examining the role of study-
specific covariates in predicting the observed SDs. Stevens
et al. [15] implement the same technique in a network
meta-analysis of treatments for intermittent claudication.
Boucher [16] imputes missing variances using a non-
linear mixed effects Emax model of SDs over time in the
specific scenario where longitudinal measurements of a
pain outcome are available but not all SDs are reported.
The SD for study i, treatment group j, time point k is
modelled as
SDijk ¼ E0 þ
E max0  1−I j
 þ E max1  I j 
et50 þ tijk þ ηi þ ξ ijk
where E0 is the estimated baseline SD, Emax0 and
Emax1 are the maximum difference over baseline for
treatment groups 0 and 1 respectively, Ij is an indicator
variable for treatment group, et50 is the time post first
dose when 50% of the maximal difference over baseline
is reached, tijk is the time post first dose, ηi  Nð0; σ2bsdÞ
is the between study variability, and ξ ijk  Nð0; σ2sd=nijkÞ
is the residual. Maximum likelihood and Bayesian ap-
proaches to estimation are investigated. Weak priors are
used so that only the observed SDs inform the missing
data imputation. A joint model encompassing missing
SD imputation and the final meta-analysis ensures that
uncertainty in the imputed values is carried forward to
the meta-analysis. He concludes that a Bayesian model-
ling approach holds advantages (in terms of appropriate
propagation of uncertainty) over maximum likelihood
techniques. Either approach would require unreported
SDs to be missing completely at random.
Chowdhry et al. [25] impute missing variances for
meta-analyses of parallel group and cross-over trials
using a gamma meta-regression generalised linear mixed
model, additionally taking study covariates into account
when modelling the variance. The study random effect
reflects the reasonable assumption that the between-
study variation in variance cannot entirely be explained
by the available covariates. They perform inference on
the mean treatment difference using multiple imput-
ation. The method depends on the missing at random
(MAR) assumption regarding unreported variances.
They propose sensitivity analyses via a pattern mixture
model if variances are missing not at random (MNAR).
The approach may benefit from a large number of trials
being included in the meta-analysis: their motivating ex-
ample covers 84 parallel group trials. Their extensive
simulation studies demonstrate the superior perform-
ance of the method with regard to Type I error and
coverage, in comparison to single imputation approaches
such as that of Ma et al. [23] or the complete case ap-
proach (found in 9% of meta-analyses by Wiebe et al. [5]
in which trials with missing variances are omitted from
meta-analysis. They conclude that the advantages are
smaller than expected, primarily because the missing
variances influence only the weighting applied in the
meta-analysis.
Missing mean methods
The search was run on 12 November 2014, and updated
using the cited reference search of Hozo and colleagues
[6] on 4 April 2016 and the survey of Cochrane topic ex-
perts in May 2016. Fig. 2 shows the numbers of papers
identified, screened, assessed for eligibility and included.
Following title and abstract screening 44 papers were se-
lected for full text review, of which 29 were systematic
reviews and 15 were methodology papers. From these,
24 papers discussing or implementing methodology to
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replace missing mean values were identified. A diversity
of approaches was considered but only three [17, 21, 22]
presented novel methodology for estimation of a missing
mean.
Category 1. Methods to derive mean algebraically
Hozo and colleagues [6] present methods for deriving a
missing mean value where data are available on the
median, minimum, maximum and sample size:
x ≈
aþ 2mþ b
4
þ a−2mþ b
4n
They note that where n is large, the right-hand
term in the equation becomes negligibly small and
may be omitted. In simulations they confirm that for
Normally-distributed data, the formula closely esti-
mates the true mean (within 4% across all scenarios
studied), although for larger sample sizes the median
was a more accurate estimator. For skewed data, the
counter-intuitive result is that the median is a better
estimator of the mean for larger samples (about 25 or
more), despite the above formula incorporating add-
itional information on the minimum, maximum and
sample size.
Bland [21] takes account of the extended scenario
where information on the lower (q1) and upper (q3)
quartiles is also available:
x ≈
nþ 3ð Þaþ 2 n−1ð Þ q1þmþ q3ð Þmþ nþ 3ð Þb
8n
Bland additionally notes that such quantile based
methods readily apply even if log-transformation of an
outcome seems appropriate: the log-transformed quan-
tiles may be used in the above formula to estimate the
mean of the log-transformed outcome. This is of par-
ticular interest in the case of skewed data, where unre-
ported mean values are more likely. Simulation studies
based on Normally-distributed data show that the mean
estimation formula of Bland shows minimal bias. For
skewed data, the mean estimation approach shows
somewhat less than half the bias found in the method of
Hozo and colleagues [6]. Bland observes that in meta-a-
nalysis, the interest will often be in the difference be-
tween treatment group means and any bias in mean
estimation would therefore cancel out as it would be
present in both groups.
Wan et al. [22] provide a further method which ap-
plies in situations where the lower (q1) and upper
(q3) quartiles are available but the minimum and
maximum are not.
Fig. 2 Systematic review of methods to derive missing mean: PRISMA Flow Diagram.Flow diagram based on: Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med
6(6): e1000097. https://doi.org/10.1371/journal.pmed1000097
Weir et al. BMC Medical Research Methodology  (2018) 18:25 Page 9 of 14
x ≈
q1þmþ q3
3
They also provide simplified versions of the equations
provided by Hozo et al. [6] and Bland [21], as well as an
Excel spreadsheet to aid practical implementation which
contains all of their formulae as well as those of Hozo et
al. [6] and Bland [21]. Simulations show the Wan et al.
[22] formula estimates the mean unbiasedly in the case
of Normally-distributed data; for skewed data according
to the log-Normal, Beta, Weibull or Exponential distri-
butions, at larger sample sizes (greater than n = 100) it
provides a smaller relative error in the mean estimation
than the approach of Bland, even though it does not in-
clude the minimum and maximum summary statistics.
Kwon and Reis [17] also apply the simulation-based
approximate Bayesian computation (ABC) approach de-
scribed in the missing variance/SD/SE section to esti-
mate missing mean values. In simulation studies they
find that for a sample size above 40 ABC performs con-
sistently better than the methods of Hozo et al.[6], Bland
[21] and Wan et al. [22] across all scenarios; its benefit
is greatest where the underlying continuous outcome
distribution is skewed or heavy-tailed. The average rela-
tive error of ABC estimation of the mean is almost zero
for sample sizes over 100. The ABC approach does how-
ever require the underlying probability distribution (for
example, log-Normal) to be specified in advance; the
performance of the method under model misspecifica-
tion was not investigated.
Category 2. Summary statistic level imputation
As also observed in the review by Wiebe et al. [5], many
studies applied sensitivity analysis to evaluate the impact
of imputation strategies. For example, Fedorowicz et al.
[26] planned to implement best and worst case scenarios
(worst observed trial mean for intervention and best trial
mean for comparator; and vice versa) as sensitivity ana-
lysis imputation strategies, citing the Cochrane
Handbook [4] guidance on dealing with missing data.
Method evaluation using individual participant data
We implemented illustrative meta-analyses, selecting the
subset of methods identified in the systematic reviews
that we considered most readily applicable by systematic
reviewers without the requirement for specialist software
or programming skills. For handling missing SD/SE/vari-
ance summaries we selected the single imputation ap-
proach of Ma and colleagues [23], the look-up table
method of Walter and Yao [18] and the Cochrane
Handbook [4] formula (which takes a very similar form
to that of Wan et al. [22]). For dealing with missing
mean values, we applied the formula of Hozo and col-
leagues [6] as an important reference method; in
addition, we implemented the algebraic recalculations
presented by Bland [21] and Wan et al. [22].
Table 2 shows the results of the illustrative analyses for
missing SD/SE/variance, for the selected methods versus
the comparators of (1) complete data set analysis and (2)
omitting trials with missing data. There was little differ-
ence across methods in terms of bias in the estimated
Table 2 GALA results: missing SD
Method for missing SD replacement
Complete data result Ma [23] Walter [18] Cochrane Handbook [4] None, omit study
Mean difference
(days)
95% confidence
interval
Bias Imprecision Bias Imprecision Bias Imprecision Bias Imprecision
Scenario
5 trials − 0.01 (− 0.87, 0.85)
2 missing SD 0.21 1.18 0.05 1.05 −0.01 0.73 0.27 1.28
10 trials −0.01 (− 0.37, 0.35)
2 missing SD 0.04 1.04 −0.01 1.01 −0.02 1.97 0.02 1.06
5 missing SD −0.03 1.56 0.01 1.10 −0.12 2.40 0.00 1.64
20 trials 0.00 (−0.31, 0.30)
5 missing SD 0.07 1.26 0.02 1.02 0.06 2.74 0.02 1.25
10 missing SD 0.26 2.20 0.02 1.07 0.17 3.93 0.05 1.41
30 trials −0.01 (−0.28, 0.25)
5 missing SD 0.06 1.11 0.03 1.06 −0.12 2.23 0.09 1.15
10 missing SD −0.09 1.49 −0.01 1.13 −0.21 2.45 −0.02 1.62
15 missing SD −0.03 1.87 0.02 1.17 −0.23 2.28 0.12 2.19
Results are given for mixed sample size scenario (average of 60 patients per trial) and random allocation of trials to missing SD values. Imprecision is the ratio of
the widths of the confidence intervals for the intervention effect [width when estimating missing SDs: width when all SDs available]. Results for other scenarios
(small trials, large trials; missing SD in small trials, large trials) show similar patterns and are available in online Additional file 3 Tables S1-S8
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mean difference, which was at most 0.23 days in magni-
tude and varied little across meta-analysis scenarios. In
contrast, the imprecision in the estimate of the mean
treatment effect increased substantially with the propor-
tion of trials with missing SDs (for example the confidence
interval width increased by a factor of 2.19 when 15 of 30
trials had a missing SD and those trials were omitted from
the meta-analysis). The method of Walter and Yao gave
greatest protection against this increased imprecision, per-
forming better than all alternative methods in every sce-
nario. Its imprecision was at most 1.17, in cases
where 15 of 30 trials had a missing SD.
Table 3 gives the findings for the missing mean illus-
trative meta-analyses in a similar format. In general bias
was low, with the exception of the Hozo method which
showed notable bias in meta-analyses containing 20 tri-
als. The Wan formula exhibited minimal imprecision
across all scenarios, outperforming all other methods.
The exception was for 5-trial meta-analyses with missing
means for two trials, where the Hozo and Bland
methods also demonstrated negligible imprecision; how-
ever in this case the Wan approach showed lower bias
in the estimated treatment effect.
Discussion
These parallel reviews provide an update on current
methodological approaches to the inclusion of studies
identified during the course of a systematic review that
have a missing mean or variability summary statistic in
meta-analysis of a continuous outcome. For missing SD
values, fifteen new methods were identified in addition
to those summarised by Wiebe and colleagues [5].
Methods identified for estimating the mean were the
approximate Bayesian computation approach of Kwon
and Reis [17] and formulae from Wan et al. [22], Bland
[21] and Hozo and colleagues [6] based on specific sets
of summary statistics. Neither review identified any
new methods to meta-analyse effects on continuous
outcomes that do not use individual study mean or
variance/SD/SE; or new methods to impute effect size,
from which the mean or variance/SD/SE could be
derived.
The recent literature includes a substantial number of
methods in addition to those for missing variance/SD/SE
reviewed by Wiebe and colleagues [5] and the methods for
estimating the mean available at the time of the seminal
publication by Hozo and colleagues [6]. Nevertheless, we
support the sequence of steps proposed in the Wiebe et al.
review that systematic reviewers should follow to handle
missing trial summary data, with one notable modification.
The original sequence was (1) use algebraic recalculation
to recover missing summaries; (2) contact study authors
to retrieve the summaries; (3) use multiple imputation if
sufficiently many studies with complete information have
been included; (4) use non-parametric summaries if these
have been reported and the distribution of the outcome is
not markedly skewed; (5) use single imputation if at least
one sufficiently similar study is included in the review; (6)
summarise non-pooled data from studies with missing
summaries alongside the meta-analysis of studies without
Table 3 GALA results: missing mean
Method for missing mean replacement
Complete data result Hozo [6] Bland [21] Wan [22] None, omit study
Mean difference
(days)
95% confidence
interval
Bias Imprecision Bias Imprecision Bias Imprecision Bias Imprecision
Scenario
5 trials −0.01 (−0.87, 0.85)
2 missing means −0.20 1.00 −0.12 1.00 0.05 1.00 0.27 1.28
10 trials −0.01 (− 0.37, 0.35)
2 missing means 0.64 3.47 0.15 2.15 −0.03 1.00 0.02 1.06
5 missing means 0.12 4.35 −0.06 1.58 0.04 1.00 0.00 1.64
20 trials 0.00 (−0.31, 0.30)
5 missing means 1.16 3.67 0.38 2.30 −0.03 1.00 0.02 1.25
10 missing means 1.02 4.34 0.34 2.66 0.01 1.00 0.05 1.41
30 trials −0.01 (−0.28, 0.25)
5 missing means 0.02 1.43 0.01 1.15 0.01 1.00 0.09 1.15
10 missing means 0.01 2.92 0.06 1.89 0.04 1.00 −0.02 1.62
15 missing means −0.19 3.26 −0.05 2.13 0.03 1.00 0.12 2.19
Results are given for mixed sample size scenario (average of 60 patients per trial) and random allocation of trials to missing mean values. Imprecision is the ratio
of widths of confidence intervals for the intervention effect [width when estimating missing means: width when all means available] Results for other scenarios
(small trials, large trials; missing mean in small trials, large trials) show similar patterns (online Additional file 3 Tables S9-S16)
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missing summaries; and (7) perform weighted meta-
analytic tests, avoiding mean or SD summaries and in-
stead making use of available p-value and sample size
information. We add a further recommendation: after
step (2), that approximate algebraic calculations such
as those of Hozo, Bland and Wan should be
attempted if study authors have not provided the re-
quired data. Our rationale is that approximate alge-
braic approaches will be readily implementable by the
vast majority of systematic reviewers, whereas step (3)
requires specialist statistical expertise and subsequent
steps require further assumptions or do not fully in-
corporate the study missing a summary statistic in
the meta-analysis.
The Bayesian methodologies identified in the review
contributed to two areas. First, approximate Bayesian
computing was implemented to estimate the missing
summary statistic [17]. ABC enables estimation when
the full likelihood function cannot be enumerated, as
is often the case in meta-analysis, where the data
available are study level summaries rather than indi-
vidual level data. Secondly, Bayesian strategies con-
tributed all of the new meta-analysis level methods
identified in our reviews [9, 10, 11, 12, 13, 14, 15, 16,
17]. In general these approaches utilised Bayesian
hierarchical modelling to represent the meta-analysis
data structure. Missing SD or mean values were ei-
ther imputed following assignment of a vague prior
distribution or were estimated by sampling from an
empirical prior drawn from studies which did report
the relevant summary statistic.
We highlight three main considerations for system-
atic reviewers when selecting a method for handling
missing mean or variability summaries: applicability;
assumptions; and availability of the required data.
Applicability
While Bayesian hierarchical modelling and approxi-
mate Bayesian computation offer much flexibility for
systematic review groups in which this expertise is
present, these methods are not currently available in
standard meta-analysis software and therefore remain
unavailable to the majority of systematic reviewers. In
contrast, the approximate algebraic approaches of
Hozo [6], Bland [21] and Wan [22] are readily applied
in Excel and statistical software. The single imput-
ation approach of Ma et al. [23] and the look-up
table in Walter and Yao [18] are also reasonably ac-
cessible. Ease of use of a particular method must of
course be balanced against its assumptions, so for ex-
ample sensitivity to the assumption of Normality in-
herent in approximate algebraic approaches would
require careful evaluation.
Assumptions
Many of the methods described in this review assume
that data are Normally distributed. Skewness, or other
non-Normal features, may be the underlying reason for
an SD or mean being absent from a clinical trial report
and so any method will need to be robust to deviations
from Normality. Encouragingly, despite having theoret-
ical dependence on Normality, many methods per-
formed well when estimating the mean or SD from data
with log-Normal, Weibull, Exponential or Beta
distributions.
When mean or SD data are missing in a trial report, it
is essential to investigate possible mechanisms that
would have led to this, and to use this knowledge when
choosing an imputation method [27]. Almost all of the
identified methods in this review assumed that the rele-
vant summary statistics would be missing completely at
random or at best, missing at random. The plausibility
of such assumptions will often be questionable, and so
conducting appropriate sensitivity analyses to explore
the assumptions of the selected imputation method will
also form an essential part of the process. The strategy
which omits studies with missing summary statistics
from the meta-analysis should be one such sensitivity
analysis, given its relatively strong performance across
our illustrative meta-analysis scenarios.
Availability of data
In the event of a mean or SD being unreported for a clin-
ical trial, there is also no guarantee that summary statistics
required by the methods identified in this review would be
available. We therefore caution against advocating a single
approach. Several methods could be applied within a sin-
gle meta-analysis, on a trial-by trial basis, depending on
which statistics were available for each trial. The ease of
applicability and strong estimation performance of the
Walter and Yao method for missing SDs cannot be utilised
if the minimum and maximum values (or range) of the
data are unreported. Similarly, the straightforward method
of Wan estimates the mean well but requires information
on the median and lower and upper quartiles. For ex-
ample, in a systematic review of early-supported discharge
interventions following acute stroke [28], the minimum
and maximum of the hospital length of stay outcome were
reported in four of eight original trial publications (50%)
and its median, lower and upper quartiles were reported
for two of eight trials (25%). This emphasises the import-
ance of having a suite of methods available to handle un-
reported summary statistics.
For continuous outcomes which have a highly skewed
distribution, it remains an open question whether basing
a meta-analysis on the mean treatment effect is the most
appropriate approach. Future research should investigate
alternative approaches not based on the mean, for
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example building on the work of Higgins and colleagues
[29] which enables results from the original and log-
transformed scales to be combined in a meta-analysis to
provide a geometric mean summary of treatment effect.
When a meta-analysis of a highly skewed outcome is
based on mean and SD summary statistics, the implicit
assumption is that the systematic review will have identi-
fied enough sufficiently large trials that the central limit
theorem would apply. We note that this will not univer-
sally be the case in all areas of medicine or for the full
range of research questions addressed by meta-analysis.
Our review had a number of strengths and limitations.
Because of the frequent usage of the search terms of
interest (mean, standard deviation) in manuscript text it
was a challenge to develop a sufficiently specific elec-
tronic search which was also sensitive. This, and the pat-
tern of duplicate hits across electronic database sources
in the SD methods search, led us to narrow the scope of
the electronic searching for methodology to handle
missing mean values to the EMBASE database only. We
offset this limitation by performing cited reference
searching on known key papers and by surveying topic
experts from the Cochrane Statistics Methods Group.
This also provided assurance that our review findings re-
flect the current state of the art, given the time gap from
our original electronic searching to reporting. Our use
of multiple sources (electronic, grey literature, expert
opinion) provides protection against publication bias.
The lack of a substantial treatment effect on the length
of stay outcome in our illustrative meta-analyses using
GALA trial [7] data may have limited the extent to
which the potential bias of the selected methods could
be evaluated. By presenting the mean and SD/SE/vari-
ance reviews together, we provide a single resource for
systematic reviewers seeking guidance on the issue.
Conclusions
Ultimately, full reporting of the original trial data is prefera-
ble [30] to any efforts to recover missing mean or SD
values. Nevertheless, the range of methods identified in this
review remain important as they allow systematic reviewers
performing meta-analysis to incorporate as much informa-
tion as possible from completed trials which have already
reported, often giving an advantage over the omission of
trials with missing mean or SD values from a meta-analysis.
Additional files
Additional file 1: Fig. S1. Example EMBASE search for methods to
replace missing variance, SD or standard error. (DOCX 20 kb)
Additional file 2: Fig. S2. Example EMBASE search for methods to
replace missing mean. (DOCX 20 kb)
Additional file 3: Tables S1-S8. GALA results: missing SD. Tables S9-
S16. GALA results: missing mean. (DOCX 83 kb)
Abbreviations
ABC : Approximate Bayesian Computation; SD: Standard deviation;
SE: Standard error
Funding
This project was funded by The Stroke Association, grant number 2012/05
with additional support from the Rosetrees Trust. CJW was supported in this
work by NHS Lothian via the Edinburgh Clinical Trials Unit. MCB is funded by
the Chief Scientist Office, Scottish Government’s Health and Social Care
Directorate. None of the funding sources had any role in the study design; in
the collection, analysis and interpretation of the data; in the writing of the
report; or in the decision to submit the article for publication. The views are
those of the authors and not necessarily those of the funders.
Availability of data and materials
Not applicable.
Authors’ contributions
CJW, MCB, GDM, SCL and PL conceived and designed the study. IB and CJW
performed the systematic reviews and extraction of information on included
studies. VA carried out the illustrative meta-analyses using the GALA trial
data. All authors had a role in drafting and critically revising the content of
the manuscript; and have read and approved the final version.
Ethics approval and consent to participate
The research did not directly involve human participants or human tissue.
Ethical approval was granted by the ethics committee of the Centre for
Population Health Sciences, Usher Institute of Population Health Sciences
and Informatics, University of Edinburgh. Details of ethics approval for GALA
trial (data set used in illustrative meta-analysis scenarios) provided in
reference [7].
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Usher Institute of Population Health Sciences and Informatics, University of
Edinburgh, Edinburgh, UK. 2Institute of Cardiovascular and Medical Sciences,
University of Glasgow, Glasgow, UK. 3Nursing, Midwifery and Allied Health
Professions Research Unit, Glasgow Caledonian University, Glasgow, UK.
Received: 6 September 2017 Accepted: 20 February 2018
References
1. Garrattini S, Jacobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al.
Evidence-based clinical practice: overview of threats to the validity of
evidence and how to minimise them. Eur J Intern Med. 2016;32:13–21.
2. Egger M, Smith GD, Meta-analysis PAN. Principles and procedures. Br Med J.
1997;315:1533–7.
3. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, et al.
Systematic review of the empirical evidence of study publication bias and
outcome reporting bias. PLoS One. 2008;3:e3081.
4. Higgins JPT, Green S. Cochrane Handbook for systematic reviews of
interventions version 5.1.0 [updated march 2011]. The Cochrane Collaboration.
2011. http://handbook-5-1.cochrane.org/. Accessed 27 February 2018.
5. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJA.
Systematic review identifies a lack of standardization in methods for
handling missing variance data. J Clin Epidemiol. 2006;59:342–53.
6. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the
median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
7. GALA Trial Collaborative Group. General anaesthesia versus local anaesthesia
for carotid surgery (GALA): a multicentre, randomised controlled trial.
Lancet. 2008;372:2132–42.
Weir et al. BMC Medical Research Methodology  (2018) 18:25 Page 13 of 14
8. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
9. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously
reported trials assessing change from baseline. Stat Med. 2005;24:3823–44.
10. Sung L, Beyene J, Hayden J, Nathan PC, Lange B, Tomlinson GAA. Bayesian
meta-analysis of prophylactic granulocyte colony-stimulating factor and
granulocyte-macrophage colony-stimulating factor in children with cancer.
Am J Epidemiol. 2006;163:811–7.
11. Nixon RM, Muller E, Lowy A, Flavey H. Valsartan vs. other angiotensin II
receptor blockers in the treatment of hypertension: a meta-analytical
approach. Int J Clin Pract. 2009;63:766–75.
12. Dakin HA, Welton NJ, Ades AE, Collins S, Ormec M, Kelly S. Mixed treatment
comparison of repeated measurements of a continuous endpoint: an
example using topical treatments for primary open-angle glaucoma and
ocular hypertension. Stat Med. 2011;30:2511–35.
13. MacNeil MA, Graham NAJ. Enabling regional management in a changing
climate through Bayesian meta-analysis of a large-scale disturbance. Glob
Ecol Biogeogr. 2010;19:412–21.
14. Stevens JWA. Note on dealing with missing standard errors in meta-analyses
of continuous outcome measures in WinBUGS. Pharm Stat. 2011;10:374–8.
15. Stevens JW, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, et al. Systematic
review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the
treatment of intermittent claudication. Br J Surg. 2012;99:1630-38.
16. Boucher M. Imputation of missing variance data using non-linear mixed
effects modelling to enable an inverse variance weighted meta-analysis of
summary-level longitudinal data: a case study. Pharm Stat. 2012;11:318–24.
17. Kwon D, Reis IM. Simulation-based estimation of mean and standard
deviation for meta-analysis via approximate Bayesian computation (ABC).
BMC Med Res Methodol. 2015;15:61.
18. Walter SD, Yao X. Effect sizes can be calculated for studies reporting
ranges for outcome variables in systematic reviews. J Clin Epidemiol.
2007;60:849–52.
19. Mendehall W, Ott L, Scheaffer RL. Elementary survey sampling. Belmont, CA:
Dufbury Press; 1971. p. 7–41.
20. Tippett LHC. On the extreme individuals and the range of samples taken
from a normal population. Biometrika. 1925;17:364–87.
21. Bland M. Estimating mean and standard deviation from the sample size,
three quartiles, minimum, and maximum. Int J Stat Med Res. 2015;4:57–64.
22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
deviation from the sample size, median, range and/or interquartile range.
BMC Med Res Methodol. 2014;14:135.
23. Ma J, Liu W, Hunter A, Zhang W. Performing meta-analysis with incomplete
statistical information in clinical trials. BMC Med Res Methodol. 2008;8:56.
24. Lunn DJ, Thomas A. Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling
framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37.
25. Chowdhry AK, Dworkin RH, McDermott MP. Meta-analysis with missing
study-level sample variance data. Stat Med. 2016;35:3021–32.
26. Fedorowicz Z, Carter B, de Souza RF. De Andrade lima Chaves C, Nasser M,
Sequeira-Byron P. Single crowns versus conventional fillings for the
restoration of root filled teeth. Cochrane Database Syst Rev. 2012; https://
doi.org/10.1002/14651858.CD009109.pub2.
27. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al.
The prevention and treatment of missing data in clinical trials. N Engl J
Med. 2012;367:1355–60.
28. Early supported discharge Trialists. Services for reducing duration of hospital
care for acute stroke patients. Cochrane Database Syst Rev. 2009; https://
doi.org/10.1002/14651858.CD000443.pub2.
29. Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data:
combining results reported on log-transformed or raw scales. Stat Med.
2008;27:6072–92.
30. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT. 2010
Statement: updated guidelines for reporting parallel group randomised
trials. Trials. 2010;11:32.
31. Patil A, Huard D, PyMC FCJ. Bayesian stochastic modelling in python. J Stat
Softw. 2010;35:1–81.
32. Python Software Foundation. 2006. http://www.python.org/psf/. Accessed
27 February 2018.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Weir et al. BMC Medical Research Methodology  (2018) 18:25 Page 14 of 14
